Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yves Pommier

Showing results (1-10 of 624) with videos related to

Pageof 63
Sort By:
ACS Chemical Biology|December 25, 2012
Drugging topoisomerases: lessons and challengesYves Pommier
Chemical Reviews|May 30, 2009
DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibitionYves Pommier
Journal of Molecular Biology|May 7, 2026
Molecular Determinants of Response and Rational Drug Combinations for Antibody-Drug Conjugates (ADCs) with Topoisomerase I (TOP1) Inhibitor payloadsYves Pommier
Nature Reviews. Cancer|September 23, 2006
Topoisomerase I inhibitors: camptothecins and beyondYves Pommier
Current Medicinal Chemistry. Anti-Cancer Agents|September 24, 2004
Camptothecins and topoisomerase I: a foot in the door. Targeting the genome beyond topoisomerase I with camptothecins and novel anticancer drugs: importance of DNA replication, repair and cell cycle checkpointsYves Pommier
Cancer Biology & Therapy|November 21, 2007
Finding the interface: more than an imageYves Pommier
Cancer Research|December 15, 2010
MDC1 cleavage by caspase-3: a novel mechanism for inactivating the DNA damage response during apoptosisStéphanie Solier, Yves Pommier
Cell Cycle (Georgetown, Tex.)|May 19, 2009
The apoptotic ring: a novel entity with phosphorylated histones H2AX and H2B and activated DNA damage response kinasesStéphanie Solier, Yves Pommier
Molecular Cancer Therapeutics|April 23, 2009
The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectivesYves Pommier, Mark Cushman
Cancer Research|May 17, 2019
Phosphatase 1 Nuclear Targeting Subunit, a Novel DNA Repair Partner of PARP1Junko Murai, Yves Pommier
Pageof 63

Showing results (1-10 of 624) with videos related to

Sort By:
Pageof 63
ACS Chemical Biology|December 25, 2012
Drugging topoisomerases: lessons and challengesYves Pommier
Chemical Reviews|May 30, 2009
DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibitionYves Pommier
Journal of Molecular Biology|May 7, 2026
Molecular Determinants of Response and Rational Drug Combinations for Antibody-Drug Conjugates (ADCs) with Topoisomerase I (TOP1) Inhibitor payloadsYves Pommier
Nature Reviews. Cancer|September 23, 2006
Topoisomerase I inhibitors: camptothecins and beyondYves Pommier
Current Medicinal Chemistry. Anti-Cancer Agents|September 24, 2004
Camptothecins and topoisomerase I: a foot in the door. Targeting the genome beyond topoisomerase I with camptothecins and novel anticancer drugs: importance of DNA replication, repair and cell cycle checkpointsYves Pommier
Cancer Biology & Therapy|November 21, 2007
Finding the interface: more than an imageYves Pommier
Cancer Research|December 15, 2010
MDC1 cleavage by caspase-3: a novel mechanism for inactivating the DNA damage response during apoptosisStéphanie Solier, Yves Pommier
Cell Cycle (Georgetown, Tex.)|May 19, 2009
The apoptotic ring: a novel entity with phosphorylated histones H2AX and H2B and activated DNA damage response kinasesStéphanie Solier, Yves Pommier
Molecular Cancer Therapeutics|April 23, 2009
The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectivesYves Pommier, Mark Cushman
Cancer Research|May 17, 2019
Phosphatase 1 Nuclear Targeting Subunit, a Novel DNA Repair Partner of PARP1Junko Murai, Yves Pommier
Pageof 63